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Produced from the pathogenicity islands of Staphy-
lococcus aureus clinical isolates, stable SprG1 RNA
encodes two peptides from a single internal reading
frame. These two peptides accumulate at the
membrane, and inducing their expression triggers
S. aureus death. Replacement of the two initiation
codons by termination signals reverses this toxicity.
During growth, cis-antisense RNA SprF1 is ex-
pressed, preventing mortality by reducing SprG1
RNA and peptide levels. The peptides are secreted
extracellularly, where they lyse human host erythro-
cytes, a process performed more efficiently by the
longer peptide. The two peptides also inactivate
Gram-negative and -positive bacteria, with the
shorter peptide more effective against S. aureus
rivals. Two peptides are secreted from an individual
RNA containing two functional initiation codons.
Thus, we present an unconventional type I toxin-anti-
toxin system expressed from a human pathogen pro-
ducing two hemolytic and antibacterial peptides
from a dual-coding RNA, negatively regulated by a
dual-acting antisense RNA.
INTRODUCTION
The Staphylococcus aureus bacterium is a serious human path-
ogen that causes life-threatening nosocomial and community-
associated infections (Anstead et al., 2014). S. aureus generates
virulence factors (Zecconi and Scali, 2013) whose timing and
expression levels are tuned by regulatory proteins and small
RNAs (sRNAs). Bacterial sRNAs control the expression of targets
such as virulence and stress response genes directly or indirectly
through regulatory cascades (Caldelari et al., 2013). Direct regu-
lations are achieved through pairing with mRNA targets by
sharing limited or extended complementarity or by modulating
protein activity (Storz et al., 2011). As for Listeria monocytogenes
(Mellin and Cossart, 2012) or Streptococcus pneumoniae (Mann
et al., 2012), S. aureus expresses hundreds of sRNAs, making it
a model organism for sRNA studies in Gram-positive bacteria
(Guillet et al., 2013; Tomasini et al., 2014). In S. aureus, several424 Cell Reports 7, 424–435, April 24, 2014 ª2014 The AuthorssRNAs are expressed from small pathogenicity islands (SaPIs)
containing virulence and antibiotic resistance genes; thus, these
sRNAs have been named ‘‘Spr’’ (small pathogenicity island
RNAs). Interestingly, one of these, SprD, contributes to disease
induction in a mouse model of infection and reduces the expres-
sion of a host immune evasion molecule (Chabelskaya et al.,
2010). Recent reports suggest that some sRNAs, originally
termed ‘‘noncoding regulatory RNAs,’’ encode peptides or small
proteins from internal reading frames (Vanderpool et al., 2011;
Sayed et al., 2012a).
This study investigated the functions of SprF and SprG, RNA
present in multiple copies in the staphylococcal genome and
initially detected by computer searches and transcriptomic
analysis (Pichon and Felden, 2005). Sequence comparisons
suggested that the SprF1/SprG1 pair might be a type I toxin-
antitoxin (TA) system (Fozo et al., 2010). TA systems are classi-
fied into five types depending on the nature and mode of action
of the antitoxin. In types I and III, the antitoxins are RNA that
either inhibit toxin synthesis or that sequester the toxins. In types
II, IV, and V, the antitoxins are proteins that sequester toxins,
counterbalance toxin activity, or inhibit toxin synthesis. Type I
TA systems are abundant in the eubacterial and archaeal
genomes and are made of overlapping gene pairs that allow
toxic peptide expression, which is then neutralized by an anti-
sense RNA antitoxin (Brantl, 2012). They permit plasmid mainte-
nance or act as stability modules for their genomes (Holcı´k and
Iyer, 1997; Van Melderen, 2010). When overexpressed, some
of these pairs trigger cell death, whereas others contribute to
formation of persister cells, thus inducing a dormant stage
tolerant to certain antibiotics (Do¨rr et al., 2010). However, the
precise roles of these TA systems remain obscure. We report
here that the SprG1/SprF1 pair is an unconventional type I TA
system expressed in S. aureus. SprG1 uses two in-frame initia-
tion codons to produce two toxic peptides. Peptide expression
is negatively regulated by SprF1, a dual-acting cis-antisense
RNA. The two secreted peptides are able to lyse host cells and
competing bacteria with dissimilar strengths.
RESULTS
SprF1 and SprG1 End Mapping, Expression, Relative
Amounts, and Stabilities
SprF and sprG read in opposite directions, with sequence
overlaps predicted at their 30 ends. Using probes specific for
Figure 1. SprF1 and SprG1 Genomic Loca-
tion, Expression Survey, Quantities, and
Stabilities in S. aureus Strain N315
(A) RACE mappings of SprF1 and SprG1 in the
FSa3 pathogenicity island of the S. aureus N315
genome, showing genomic location, length
determination, and nucleotide overlap.
(B) Northern blots detecting SprF1, SprG1439, and
SprG1312 at various times during growth. tmRNA is
an internal control.
(C) SprF1, SprG1439, and SprG1312 quantifications
relative to increasing amounts of synthetic SprF1
and SprG1.
(D) SprF1 and SprG1RNA expression levels during
growth after addition of rifampicin, relative to the
5S rRNA, used as an internal control.
(E) Quantification of SprG1312 (black squares)
and SprF1 (white squares) RNA levels after rifam-
picin addition (Arbitrary Units, AU). The error bars
indicate variations between three replicates.each identified gene copy, we found three strains that did not
express SprF1 and SprG1, whereas the copies were expressed
in all other strains tested. There was some ambiguity in certain
strains as to the presence of SprG2 and SprG4, probably due
to their sequence similarities (Figure S1). We chose to work
with strain N315 because it is a clinical, Methicillin-resistant
S. aureus strain (MRSA) that expresses all the gene copies.
RACE mapping was done to determine the 50 and 30 ends of
the four SprF/G RNA pairs present in this strain (Table S1).
This report focuses the SprF1/SprG1 pair located within
FSa3 PI, which is the genome of a virulence factor-containing
converting phage (Pichon and Felden, 2005), compared to
the other copies located in the core genome. The SprF1 and
SprG1 30 ends overlapped, excluding only seven nucleotides
(nt) at the SprF1 50 end (Figure 1A). Northern blot and RACE
mapping of SprG1 indicated that it is expressed as two tran-
scripts differing at their 50 ends: a SprG1312 major form, and
a SprG1439 minor form (Figure S2). Long and short SprG1
have conserved –10TATTA–6 and –9TATAAT–4 boxes, respec-
tively, as predicted promoters (Figure S3, red). The SprF1 50
end was assigned at position A2010870 downstream of a pre-
dicted conserved –21TATATTA–15 promoter sequence (Fig-
ure S4, red). SprG1 and SprF1 expression were monitored
during S. aureus growth (Figure 1B). During growth, the RNAs
are constitutively and concomitantly expressed. Quantitative
estimations of SprF1, SprG1439, and SprG1312 were done
by comparing their in vivo expression to a concentration
range of purified synthetic RNA (Figure 1C). At all times,
there was about twice the amount of SprG1312 as of SprF1,Cell Reports 7, 424–4whereas the expression of SprG1439
was about 20-fold less than that of
SprG1312. Half-life determinations of the
RNAs (Figures 1D and 1E) showed about
a 12-fold shorter half-life for SprF1
(10 min) than for SprG1312 (>120 min).
In summary, unstable SprF1 and stableSprG1 are constitutively expressed, and their RNA sequences
overlap.
SprG1 Ribosome Loading at Two Internal Initiation
Codons Generates Two Peptides
SprF1 and sprG1 phylogenetic distribution is restricted to the
Bacillales (staphylococcaceae, genus staphylococcus), with an
increased sequence identity between the strains (Figures S3
and S4). In all identified sprG1 sequences, an internal open
reading frame (ORF) was identified with two predicted Shine-
Dalgarno (SD) sequences 8 nt upstream from two potential
initiation codons (Figure S3, underlined). SprG1 may therefore
express two polypeptides: one containing 44 amino acids with
a predictedmolecular weight (MW) of5 kDa; and a shorter pep-
tide of 3.5 kDa theoretical MW that lacks 13 residues at the N
terminus (Figure 2A). A probable ORF was also detected in
SprF1 (Figure S4). To determine whether SprF1 and/or SprG1
express peptides, in vitro translation assays were performed
(Figure 2B). No translation was detected with SprF1. Synthetic
SprG1312 and SprG1439 RNA, however, produce peptides of
3–5 kDa apparent MW, which is in agreement with the peptide
lengths inferred from the internal coding sequence. To investi-
gate whether translation initiates at one or both predicted methi-
onine codons, they were replaced by two termination codons
(mutant SprG1439-STOP1,14), but this interrupted translation.
Next, to test whether the short peptide encoded by SprG1 arises
from initiation at the second in-frame methionine codon (M14),
it was mutated into Alanine (mutant SprG1439-Ala14). Mutating
M14 into Ala14 caused a strong inhibition of the short peptide35, April 24, 2014 ª2014 The Authors 425
Figure 2. SprG1 Expresses Two Peptides
from Two In-Frame Methionine Codons
Whose Expression Is Inhibited by SprF1
(A) Top: location of the internal ORFs (red and
green) within the SprG1 sequence, with SprF1
bordering the predicted stop codon of the ORFs.
Bottom: amino acid sequences and mutations
performed on the two peptides. The two methio-
nine initiation codons M1 (red) and M14 (green) and
the valine initiation codon V2 (blue) were mutated
into termination codons (STOP1, STOP2, STOP1,2,
STOP14, and STOP1,14) or into an alanine codon
(Ala14).
(B) In vitro translation assays detected 3.5
and 5 kDa peptides (arrowheads) expressed
by SprG1312, SprG1439, SprG1439-STOP1,14, and
SprG1439-Ala14 RNAs in the absence or presence
of SprF1. SprF1 is in 2.5 molar excess as
compared to SprG1.
(C and D) Two experimentally determined ribo-
some toeprints on SprG1312 (arrows). (C) U, C, G,
and A refer to the SprG1312 sequencing ladder. (D)
The AUG codons and the SD sequences are bold
and underlined. The internal coding sequence of
SprG1 is red.translation, although translation of the long peptide was main-
tained. This suggests that the shorter peptide was produced
from ribosome initiation at M14. When SprF1 is added to the
reaction at a 2.5-fold molar excess as compared to SprG1,
SprG1312, and SprG1439 translations were reduced about 3-
and 2-fold, respectively. The direct interaction of the ribosomes
with the predicted translation initiation signals was evaluated
using toeprint assays on ternary initiation complexes that
included purified ribosomes, initiator tRNAfMet, and SprG1312
(Figure 2C). Two ribosome toeprints were detected at posi-
tions A89 and G135 on SprG1, 15 and 23 nt downstream, respec-
tively, from A+1 of the first and second predicted initiation
codons in the SprG1 ORF (Figure 2D).
The SprG1-Encoded Peptides Originate from Two
Internal In-Frame Methionine Codons
To investigate whether SprG1 produced the two peptide(s)
in vivo during bacterial growth, a reporter construct was de-426 Cell Reports 7, 424–435, April 24, 2014 ª2014 The Authorssigned by adding an 2.75 kDa theo-
retical MW 3 3 FLAG (FLAG) sequence
in-frame ahead of the ORF’s pre-
dicted termination codon (Figure S3).
In addition to endogenous SprG1312,
northern blots validated the expression
of SprG1312-FLAG during growth (Fig-
ure 3A). Using anti-FLAG, immunoblot-
ting revealed that SprG1 fusion peptides
are expressed in vivo during S. aureus
growth (Figure 3B). Two peptides were
detected: a major abundant form and
a minor shorter product, both of 5–
7.5 kDa apparent MWs, in agreement
with the predicted 31+22- and 44+22-amino-acid-long fusion peptides inferred from the SprG1
sequence (Figure S3). The peptides were expressed early,
accumulated during the early phase, and decreased later on.
This drop in peptide expression was not caused by a toxicity-
induced cell plasmid number reduction (see below) because
the SprG1312-FLAG RNA levels were stable throughout growth
(Figure 3A). Compared to S. aureus cells with an empty vector,
isogenic bacteria expressing SprG1312-FLAG had reproducible
minor growth defects (Figure 3C). To determine whether
SprF1 effects SprG1-encoded peptide expression in vivo,
an additional construct was built to produce the flagged
peptides in the presence of excess SprF1. Northern blots
showed that inducing about a 3-fold increase in SprF1 expres-
sion reduced the amount of SprG1312-FLAG and SprG1312
endogenous RNA (Figure 3A), as well as reducing the number
of flagged peptides (Figure 3B), thus complementing the
growth defect (Figure 3C). To test whether the peptides
encoded by SprG1 resulted from translation initiation at two
Figure 3. SprG1 Expresses Two Membrane
Peptides from Two Internal Methionine Co-
dons Whose Expression Is Inhibited by
SprF1 during S. aureus Growth
Northern blot analysis of SprF1, SprG1312, and
SprG1312-FLAG (arrowheads) RNA expression (A),
western blot analysis of SprG1-encoded flagged
peptide expression (B), and growth kinetics (C) of
S. aureus strain N315 carrying an empty pCN35
vector (black), pCN35USprG1FLAG (gray), or
pCN35USprG1FLAG SprF1 (white).
(A) 5S rRNAs are internal loading controls.
(B) Coomassie staining of the total proteins from
each sample is loading controls.
(C) The error bars indicate variations between three
replicates.
(D) S. aureus strain N315 pCN35, pCN35U
SprG1FLAG, pCN35USprG1FLAG-STOP1, pCN
35USprG1FLAG-STOP2, pCN35USprG1FLAG-
STOP1,2, pCN35USprG1FLAG-STOP14, pCN35U
SprG1FLAG-STOP1,14, and pCN35USprG1FLAG-
Ala14 were grown to OD600nm:4, and cell lysates
were prepared. The expression of SprG1-encoded
flagged peptides was analyzed by western blot-
ting. ATPase expression was used as a loading
control.
(E) S. aureus strain N315 pCN35, pCN35USprG1
FLAG, and pCN35USprG1FLAG-STOP1,14 were
grown to OD600nm:4. After membrane and cyto-
solic preparation, expression of the SprG1-en-
coded flagged peptides was analyzed by western
blotting. ATPase and SarA expression were
used as a membrane and cytosolic controls,
respectively.internal AUG codon (M1 and M14) or at a second in-frame valine
codon (V2), they were mutated into a UAA termination codon
(Figure 2A). When compared with the fusion peptides ex-
pressed by SprG1, immunoblots revealed the lack of expres-
sion of the longer peptide in the STOP1 and STOP2 mutants,
together with a significant increase of expression of the
short peptide predicted to start at M14 (Figure 3D). In the
STOP14 mutant used as a control, no peptides were pro-
duced, because the truncated 13 residue form of the long
peptide is not flagged and thus not detected. More surprising
was the absence of peptides produced by the STOP1,2 mutant,
suggesting that the sequence at and around M1 influences
production of the shorter peptide, possibly requiring an initial
ribosome loading further upstream. Mutating M14 into Ala14
caused the disappearance of the shorter peptide while main-
taining the expression of the longer one (Figure 3D). Altogether,Cell Reports 7, 424–the mutational analysis of the initiation
codons of the SprG1 coding sequence
indicated that the long and short pep-
tides were produced from ribosome
initiation at M1 and M14, respectively.
In addition, it was determined that
specific mutations could lead to the
exclusive synthesis of the long (Ala14) orthe short (STOP1) peptides. Therefore, SprG1 stable RNA
contains a dual-coding ORF.
Both SprG1-Expressed Peptides Are Detected at the
S. aureus Membrane
The amino acid sequences of the peptides encoded by SprG1
and produced by strain N315 are conserved in all sequenced
S. aureus genomes, with minor sequence variations leading to
one to two amino acid changes in the 44 residues (Figure S5).
The second methionine codon was lacking in three species con-
taining sprG1 and sprF1. Sequence alignments and the amino
acid composition of the SprG1-encoded peptides suggested
the existence of a transmembrane hydrophobic domain and
two cationic ones. Subcellular localization of the two peptides
was performed within the S. aureus N315 cells. Membrane and
cytosolic fractions were prepared, and the cell fractionation435, April 24, 2014 ª2014 The Authors 427
Figure 4. SprF1 Reduces SprG1 Expression
by a Direct cis Interaction that Involves the
Sequence Overlap between the RNAs
(A) Native gel retardation assays of purified labeled
SprF1 (A) with unlabeled SprG1312. The com-
plexes were revealed with a Phosphoimager for
the radioactive assay. The competition assays
were performed with a 2,000-fold molar excess of
polyU RNAs or with a 10-fold molar excess of
unlabeled SprF1. The apparent binding constant
(Kd) between SprG1 and SprF1 was inferred from
three independent experiments: Kd = 1.3 ± 0.4 nM.
(B) Native gel retardation assays of SprF1 with
SprG1312, the 5
0 and ORF sequences of SprG1312
(SprG1-50-ORF), and the 30 sequence of SprG1312
(SprG1-30). The complexes were revealed by
ethidium bromide staining.
(C) Northern blot analysis of SprF1 and SprG1
expression levels during growth in a S. aureus
N315 strain carrying an empty pCN35 vector and
in an isogenic strain containing pCN35USprF1.
The 5S rRNAs are the internal controls.purity was verified by immunoblotting using anti-ATPase and
anti-SarA (staphylococcal accessory regulator) antibodies,
respectively (Figure 3E). Immunoblots with anti-FLAG indicated
that the SprG1-encoded peptides were only detected in the
membrane fractions. As negative controls, no peptides were
detected for the S. aureus strains having either an empty vector
or a STOP1,14 mutant lacking the two internal initiation codons.
This indicates that once the peptides were translated, they
migrated to the S. aureusmembranes. Despite several attempts
to monitor the expression of the native untagged peptides,
polyclonal antibodies against each of the two chemically syn-428 Cell Reports 7, 424–435, April 24, 2014 ª2014 The Authorsthesized peptides inferred from the
SprG1 sequence could not be obtained.
SprF1 Reduces SprG1 RNA
and Peptide Levels by a Direct cis
Interaction Involving Its Sequence
Overlap
SprF1 prevented SprG1312 and SprG1439
translation in vitro (Figure 2B) and in vivo
(Figure 3B) and the RNAs possess
nucleotide complementarities involving
134 nt at their 30 ends (Figure 1A). Native
gel retardation assays performed be-
tween SprF1 and SprG1312 detected
an RNA complex (Figure 4A) with an
apparent binding constant of about 1.3
± 0.4 nM. Binding is specific, because
a 2,000-fold molar excess of unrelated
RNA does not remove SprF1 from its
preformed SprF1-SprG1312 complex,
whereas a 10-fold excess of SprF1
does. Antisense RNA pairs do not
necessarily depend on their overlapping
sequences for interaction and regulation
(Sayed et al., 2012a). SprG1312 wasdivided into two halves: a SprG1-50 ORF containing its 50
domain and its ORF but without its SprF1 overlap sequence;
and SprG1-30 which includes its 30 domain that overlaps with
SprF1 (Figure 4B). Gel retardation assays indicated that
SprF1 interacts with SprG1 using its 30 domain. In the Figure 3A,
we have shown that SprF1 may lower SprG1 translation by
affecting SprG1 RNA levels. To confirm this result, a strain
overexpressing SprF1 was constructed by cloning the gene
with its endogenous promoter into pCN35. Northern blots indi-
cated that, when SprF1 is overexpressed (20-fold excess),
SprG1 was undetectable during bacterial growth (Figure 4C),
indicating that SprF1 induction reduced SprG1 RNA levels
in vivo.
Both SprG1-Encoded Peptides Inhibit S. aureus Growth
and Trigger Death
Sequence comparisons suggested that the SprG1/SprF1 pair
belongs to a type I TxpA (Toxic peptide A) TA family (Fozo
et al., 2010). To test this hypothesis, native untagged peptides
in vivo were produced from the SprG1439 sequences starting at
the upstream transcription initiation site (Figure S3), from the
STOP1, Ala14, and STOP1,14 SprG1 mutants. These were all
cloned into inducible low copy pALC vectors. After an anhydro-
tetracycline (aTc) induction, northern blots were used to verify
the in vivo production of SprG1, SprG1-STOP1, SprG1-Ala14,
and SprG1-STOP1,14 (Figure 5A). Without aTc, S. aureus cells
containing each of the four constructs grew in the same manner
as the empty vector cells (data not shown). But in the presence
of aTc, SprG1 expression inhibited S. aureus growth in liquid
cultures (Figure 5B), a process also shown by adding aTc onto
a solid media and performing serial dilutions (Figure 5C). The
SprG1-STOP1 mutant that only expressed the shorter peptide
inhibited S. aureus growth, whereas SprG1 and the SprG1-
Ala14 mutant only expressed the long peptide (Figures 3D, 5B,
and 5C). Mutant SprG1 STOP1,14, however, which does not
express either of the two peptides, grows near to wild-type
(WT) levels in both liquid and solid cultures. This demonstrates
that SprG1 inhibits S. aureus growth because it encodes two
peptides, and that the production of either of these peptides
stops growth. SprG1 also slightly impaired growth indepen-
dently of its translation products (Figure 5B). To determine
whether the SprG1-encoded peptides induce S. aureus cell
death, bacteria containing an empty pALC, pALCUSprG1, or
the SprG1-STOP1,14 mutant were stained with fluorescent dyes
to discriminate between living and dead cells and then viewed
by microscopy. For the pALC negative control, bacteria were
alive, whereas increasing SprG1 expression levels killed about
half the cells (Figure 5D). Up to 80% of the bacteria carrying
SprG1-STOP1,14, a mutant incapable of producing the two
peptides, were viable. This shows that it is the peptides, not
SprG1 alone, that are required for toxicity.
The SprG1/SprF1 Pair Is a Type I TA System that
Produces Two Toxic Peptides
Direct detoxification of the SprG1 transcript by SprF1 expres-
sion of was assayed in vivo. Two sets of plasmids were used:
an aTc-inducible pALC with or without SprG1; and a constitu-
tive pCN35 with or without SprF1 expression. Northern blots
validated SprF1 induction in Newman strains containing
pCN35USprF1 and SprG1 expression after aTc induction in
strains transformed with pALCUSprG1 (Figure 5E). In the pres-
ence of aTc, the strains containing pALC and pCN35USprF1
(and therefore expressing SprF1) grew in the same way as
those containing the two empty vectors (Figure 5F). The cells
expressing SprG1 after aTc induction, however, inhibited
S. aureus growth, and this was rescued by inducing SprF1
expression (Figure 5F). Altogether, these experiments demon-
strate that the SprG1/SprF1 pair is a type I toxin/antitoxin
system in which toxicity relies upon the internal expression oftwo peptides, with both being enough on their own to trigger
toxicity.
The SprG1 Peptides Are Secreted, and They Lyse Host
Cells and Competing Bacteria with Dissimilar Strengths
The two peptides were detected at the S. aureus membrane
(Figure 3E), possibly ready for subsequent release outside the
bacteria. To investigate this, total and extracellular proteins
were extracted at various times during S. aureus growth. The
two SprG1-encoded fusion peptides accumulated over time in
the extracellular environment in smaller amounts than in the total
cell lysates (Figure 6A). The longer peptide was predominantly
expressed and secreted, compared to the short peptide.
Although cytoplasmic SarA transcription factor was detected in
the total protein extracts, its absence within the extracellular
fractions rules out the idea that the exterior peptides are due to
cell lysis. Immunoblots against Protein A and extracellular adher-
ence protein (Eap) allowed their detection, mostly within the
extracellular fractions. This is a result consistent with that for
excreted proteins, thus it further supports our protein fraction-
ations. Peptide sequence alignments suggest that they are hy-
drophobic and contain cationic residues (Figure S5), both attri-
butes of pore-forming peptides (Hancock and Rozek, 2002).
The lytic activity of the SprG1-expressed peptides was seen
when adding increasing concentrations of each of the two syn-
thesized formylated peptides to human erythrocytes. The longer
peptide has significantly higher (5-fold) activity toward human
erythrocytes than that of the shorter peptide, and is more active
(3-fold) than d-hemolysin, the positive control (Figure 6B). As
the peptides encoded by SprG1 are secreted, they might also
inhibit the growth of competing bacteria during colonization
and infection. Their antibacterial activity against representative
Gram-positive and -negative bacteria was measured by a
growth inhibition assay in liquid cultures, using serial peptide
dilution and recording the minimal inhibitory concentration
(MIC) values (Figure 6C). Compared to nisin (a Gram-positive
antibacterial peptide) and cecropin (a Gram-negative antibacte-
rial peptide), these peptides possess moderate antibacterial ac-
tivities against S. aureus as well as against E. coli and (to a lesser
extent) Pseudomonas aeruginosa, two bacteria frequently asso-
ciated with staphylococcal infections. Interestingly, the short
peptide has a lower MIC value against S. aureus than the longer
peptide. Both peptides, however, have similar MICs against
E. coli and P. aeruginosa, and both are more active against the
former. To evaluate the antibacterial activity of the SprG1-en-
coded peptides directly produced by S. aureus during growth,
S. aureus membrane extracts were prepared from bacteria
deleted in the sprG1/sprF1 locus (negative control). These either
expressed SprG1 and therefore the two peptides, or a STOP1,14
mutant unable to produce the two peptides, and were then incu-
bated with intact S. aureus cells. Like nisin, the membrane ex-
tracts containing the two peptides encoded by SprG1 prevent
S. aureus growth (Figure 6D). Interestingly, similar amounts of
membrane extracts from strain DsprG1/sprF1 and from isogenic
strain pALC SprG1-STOP1,14 (both strains not expressing the
SprG1 peptides) allow bacterial growth in the same manner as
an isogenic WT strain. Therefore, peptides produced by growing
bacteria can prevent the growth of competing S. aureus cells.Cell Reports 7, 424–435, April 24, 2014 ª2014 The Authors 429
Figure 5. SprG1 Overexpression Triggers S. aureus Death Caused by Either Encoded Peptide and Reversed by SprF1
(A) Northern blot analysis of the expression levels of SprG1 and three SprG1 mutants (STOP1, Ala14, STOP1,14) after induction by anhydrotetracyline (aTc).
(B and C) (B) Growths in liquid cultures and (C) serial dilutions of exponentially grown N315 bacteria containing pALC (black), pALCUSprG1 (pink), pALCUSprG1-
STOP1 (green), pALCUSprG1-Ala14 (yellow), and pALCUSprG1-STOP1,14 (blue) RNA after aTc induction. The error bars in (B) indicate variations between three
replicates.
(D) Cells counts of fluorescent viable S. aureus cells after LIVE/DEAD experiments. Data were expressed as the mean ± SD of four independent experiments.
*p < 0.05; ***p < 0.001.
(E) Northern blot analysis of SprG1 and SprF1 expression levels in isogenic S. aureus Newman strains containing pALC and pCN35, pALC and pCN35-SprF1,
pALC-SprG1 and pCN35, and pALC-SprG1 and pCN35-SprF1 plasmids. The internal loading control is 5S rRNA.
(F) Growths of Newman strains containing pALC and pCN35 (black), pALC and pCN35-SprF1 (gray), pALC-SprG1 and pCN35 (pink), and pALC-SprG1 and
pCN35-SprF1 (blue) plasmids after aTc induction. The error bars indicate variations between three replicates.
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DISCUSSION
We report on an unconventional type I TA system expressed by
S. aureus: the SprG1/SprF1 pair. Type I TA systems consist of
a stable toxin whose expression kills the cells or confers growth
stasis, regulated by unstable RNA antitoxins. SprG1 is a dual-
coding RNA sequence that produces two membranes and se-
cretes toxic peptides by utilizing two internal in-frame initiation
codons. The expression of the toxic peptides is negatively regu-
lated by SprF1, a dual-acting cis-antisense RNA. Compared to
the short (5 min) half-lives of the majority of the S. aureus
mRNAs, SprG1 is a stable RNA (Roberts et al., 2006). It is ex-
pressed as two transcripts differing at their 50 ends, which can
both produce the two peptides. SprG1312 prevails at all times
during growth, whereas SprG1439 is mainly detected at later
stages, suggesting that environmental or metabolic signals
modulate promoter usage. In S. aureus, the major transcriptional
regulator SarA is also transcribed from distinct widely spaced
promoters that yield three overlapping transcripts that vary
at their 50 ends (Bayer et al., 1996) for optimal expression
regulation.
Figure 6E shows SprG1 regulation by SprF1, SprG1’s expres-
sion products, and the outcomes of this for the bacterial physi-
ology. SprG1 expression is toxic when stimulated and is tightly
protected by the unstable SprF1 antitoxin. SprF1 counteracts
SprG1 toxicity at both the RNA and peptide levels by direct
interaction in cis, which includes the SprG1-overlapping 30
domain. In type I TA systems, antitoxins either inhibit toxic
mRNA translation or promote mRNA degradation (Brantl,
2012). SprF1 performs at both of these regulatory levels,
perhaps interfering with SprG1 transcription, triggering its
degradation by dedicated RNases (Romilly et al., 2012), or by
remodeling SprG1 conformation to prevent toxic peptide trans-
lation. Surprisingly, during S. aureus growth there is twice as
much SprG1 as SprF1. The dual-acting control of SprG1 by
SprF1, and perhaps the involvement of other SprF copies, is
enough to counteract SprG1 toxicity during growth. The molec-
ular mechanisms of these regulations remain to be elucidated.
Dual-acting antitoxin has been detected in Bacillus subtilis,
with the SR4 antitoxin that controls bsrG toxin mRNA decay
and translation (Jahn and Brantl, 2013). Moreover, the lysC
riboswitch also controls translation initiation and mRNA decay
in E. coli (Caron et al., 2012).
SprG1 is an unconventional type I toxin that produces two
toxic peptides from two in-frame initiation codons. Such usage
of multiple initiation codons contributes to diversity through
expression of several peptide isoforms from a single transcript.
In bacteria, dual-coding mRNAs have already been reported.
For instance, in E. coli ClpA encodes the ATPase subunit of a
protease and uses dual translational initiation sites to produce
two proteins from a single reading frame (Seol et al., 1994).
E. coli dnaX expresses two peptides from a singlemRNA through
ribosomal frameshifting that produces distinct DNA polymerase
subunits (Tsuchihashi and Kornberg, 1990). In S. enterica, a
leader region controls the expression of an ion transporter by re-
sponding to proline levels via translation of a proline codon-rich
ORF located in that region (Park et al., 2010). Some RNAs also
possess dual functions, expressing a protein from an internalORF as well as regulating mRNA targets (Vanderpool et al.,
2011). In S. aureus, at least two sRNAs encode a peptide: RNAIII
encodes d-hemolysin (Novick and Geisinger, 2008), and SprA1
encodes a 31 amino acid-long type I toxin whose expression is
prevented by an antitoxin (Sayed et al., 2012a). If it controls
target gene expression, SprG1 may also belong to this group.
Preventing the expression of the longer peptide by mutations
increases the translation of the shorter peptide. This suggests
a possible conflict between the elongating and initiating ribo-
somes at the second, downstream AUG codon, because they
are only separated by 12 codons. In monocistronic RNAs with
two adjacent SD sequences, ribosome binding interferences
have been reported (Nishizawa et al., 2010), and this may
also occur with SprG1. SD modules located within coding se-
quences cause pervasive translational pausing (Li et al., 2012),
providing opportunities for heterologous peptide expression in
bacteria.
Inducing the expression of the two membrane peptides trig-
gers S. aureus death, possibly by generating pores. Except for
SymE, all known type I toxins are small hydrophobic peptides
acting as phage holins, forming pores in cell membranes and
impairing ATP synthesis (Brantl, 2012). The TisB toxin produces
clusters of anion-selective pores in lipid bilayers (Gurnev et al.,
2012). The SprA1 type I toxin, expressed by S. aureus, gets
inserted into the membranes (Sayed et al., 2012b). In enterobac-
teria, hydrophobic peptides have other roles, acting as modula-
tors, transporter stabilizers, or sensor kinase regulators (Alix and
Blanc-Potard, 2009). The peptides expressed by SprG1 could
possess other regulatory functions at the membrane level. Be-
tween 5% and 20% of the two membrane peptides, varying ac-
cording to the time selected during growth, are excreted in the
extracellular medium, where they can lyse host cells
and competing bacteria with dissimilar strengths. The longer
SprG1-encoded peptide is the one primarily expressed and
secreted. When compared to its shorter version, it is about three
times more active against human erythrocytes and about half as
active against competing S. aureus cells. The smaller size of a
peptide could facilitate its passage through the thick cell wall
of Gram-positive bacteria, which could account efficacy toward
S. aureus but not against Gram-negative bacteria. As opposed to
the short peptide, the longer version has a second N-ter cationic
domain containing four additional positive charges, and this is
probably responsible for its higher cytolytic effect against eryth-
rocytes. In L. lactis, E. coli, and B. brevis, increasing the positive
charges of signal peptide sequences improves secretion effi-
ciency (Ravn et al., 2003; Izard et al., 1995; Takimura et al.,
1997). Depending on environmental conditions, S. aureus may
prefer to use the second initiation codon, increasing shorter pep-
tide synthesis when a subset of cells is lysed. This is either an
altruistic community behavior or is a way to eradicate bacterial
rivals. Growth conditions that mimic the effect of the artificial
induction are currently unknown. If produced in sufficient
amounts, the membrane peptides investigate a programmed
cell death, which could promote the secretion of the peptides
able to lyse host cells and competing bacteria and the release
of virulence factors to facilitate spread of infections. Their
toxicity accounts for their obligatory repression by SprF1 during
growth. In S. aureus, the phenol-soluble modulins (PSMs) areCell Reports 7, 424–435, April 24, 2014 ª2014 The Authors 431
Figure 6. Secreted SprG1 Peptides Inactivate Host Cells and Competing Bacteria Differently: Schematic Diagram of SprG1 Regulation by
SprF1 and Roles
(A) Immunoblotting with anti-FLAG to detect the SprG1-encoded flagged peptides during growth of strain N315 pCN35USprG1FLAG in the culture supernatants.
The anti-SarA is the control for the total fraction, with anti-Protein A and anti-Eap as controls for the extracellular fractions.
(B) Hemolytic activity of increasing concentrations of the long (white) and short (black) synthetic peptides. The delta-hemolysin produced by RNAIII (gray) is a
hemolytic peptide used as a positive control. The results are expressed as a percentage of lysis compared with the 100% lysis of the positive control (1% Triton)
and are the mean ± SD of three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001.
(C) The Minimal Inhibitory Concentration (MIC) of the two peptides encoded by SprG1 onto Gram-positive and Gram-negative bacteria. Nisin and cecropin were
used as positive controls for the Gram-positive and -negative bacteria, respectively.
(D) Membrane extract antibacterial activity in liquid cultures after being purified from strains DsprG1/sprF1 (gray), isogenic pALC-USprG1 (pink), and pALC-
USprG1-STOP1,14 (blue). The growth of the S. aureusN315 strain is measured at 600 nm in the absence (5% isopropanol control, black) or presence of 230 mg/ml
of membrane extracts. Nisin (100 mg/ml, green) is used as a positive control. The error bars indicate variations between three replicates.
(E) Workingmodel summarizing the locations, outcomes, and functions of the two SprG1-expressed peptides and their negative regulation (red bar) by cis-acting
SprF1 (blue). The black arrows represent the gene pair; the short and long peptides expressed by SprG1 (black) are the small and large ovals, respectively. The
size of the gray arrows is proportional to the amount of peptides produced, as well as to their functional implications in host cells and bacterial lyses.
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proinflammatory peptides also hemolytic and secreted, as is
d-hemolysin (PSM gamma), another peptide that interacts with
membranes (Otto, 2010; Cheung et al., 2012). PSMs contribute
to S. aureus virulence (Wang et al., 2007) and biofilm maturation
(Periasamy et al., 2012). The peptides encoded by SprG1 may
also influence these biological events.
Type I TA systems are commonly found in multiple copies,
consistent with the expression of three to four sprF and sprG
copies in numerous S. aureus strains. Because there is signifi-
cant sequence conservation between these copies (Figure S6),
there might be interference and crosstalk between them. This
will be addressed in future studies by deleting each copy and
addressing its role in toxicity. Interestingly, a comparison of
‘‘wild’’ and laboratory strains of E. coli suggested that the num-
ber of copies would correspond to the ecological niche occupied
by the bacterial host (Fozo, 2012). The biological roles of type I
TA systems are unclear, but the systems aid in adaptive stress
responses, recovery from starvation, and immunity against
predators (Blower et al., 2011), and they can be temperature
sensitive (Jahn et al., 2012). Upon oxidative and acidic stress
in S. aureus, PepA1 type I toxin expression is induced, maybe
to ease bacterial escape from phagolysosomes (Sayed et al.,
2012b). Persister cells are dormant bacteria tolerant to antibi-
otics that show increased levels of TA transcripts (Do¨rr et al.,
2010). The SprG1/SprF1 pair might be involved in metabolic
dormancy and persister formation. There are differences be-
tween other type I TA modules and the SprG1/SprF1 pair,
including the fact that two toxic peptides are produced by the
pair. Based on their sequences, the additional copies of sprG
expressed in strain N315 may encode shorter peptides that are
25, 26, or 18 amino acids long for sprG2, sprG3, and sprG4,
respectively (Figure S6). These additional copies may have
acquired divergent regulatory functions. Global regulation of
virulence factor expression by type I TA systems in pathogenic
bacteria is an exciting concept, but it remains to be experimen-
tally proved.
In conclusion, the SprG1/SprF1 pair expressed by numerous
S. aureus clinical isolates is an unconventional type I TA system
producing two membrane toxins with different cytolytic acti-
vities and that are controlled by a dual-acting RNA antitoxin.
In bacterial pathogens, the programmed induction of toxin
expression from TA pairs could lead to promising antibacterial
strategies (Williams and Hergenrother, 2012) although in this
case chemical optimization will be needed to remove human
cell toxicity. Detecting the native peptides will provide direct
evidence of their expression. The next challenges are to identify
under what conditions they are expressed, and what are their
functions might be during staphylococcal growth, colonization,
and infection.
EXPERIMENTAL PROCEDURES
Strains, Plasmids, and Genetic Manipulations
Strains, plasmids, and primers are listed in Tables S2–S4. Strains were grown
at 37C in BHI buffer (Oxoid). When necessary, chloramphenicol and erythro-
mycin were added at 10 mg/ml. In pCN35USprF1, the SprF1 sequence of 187
nt upstream and 63 nt downstream was amplified from N315 genomic DNA as
a 385 bp fragment, with flanking BamHI/EcoRI sites, and inserted into pCN35
(Charpentier et al., 2004). For the flagged SprG1 constructs, amplificationfrom N315 DNA was done of an SprG1439 sequence consisting of 149 nt
upstream and 4 nt downstream. A 3XFLAG in-frame sequence of the
SprG1-encoded peptides followed by a termination codon (Zeghouf et al.,
2004) was added, resulting in a 658 bp fragment with flanking BamHI/EcoRI
sites. This was then inserted into pCN35. For the flagged SprG1 constructs
expressing SprF1, the SprG1 sequence corresponds to a 715 bp fragment
of 149 nt upstream and 61 nt downstream. In these constructs, the RNAs
were expressed from their endogenous promoters. To generate an anhydro-
tetracycline (aTc)-inducible construct for SprG1, a fragment containing the
SprG1439 sequence with +1 and 4 nt downstream was amplified from N315
DNA as a 500 bp fragment with flanking KpnI/EcoRI sites then inserted into
pALC (Bateman et al., 2001). To inactivate the sprF1/SprG1 gene pair, DNA
fragments of 1,050 bp upstream and 915 bp downstream of the sprF1/
SprG1 gene were amplified by PCR from N315 DNA and cloned into
BamHI/PstI sites of temperature-sensitive plasmid pBT2 (Bru¨ckner, 1997).
The resulting plasmid pBT2DsprF1/sprG1was transformed into S. aureus
strain RN4220 and then into S. aureus N315. Mutants were enriched by
growth at 42C. Cells from stationary-phase cultures were plated onto Trypti-
case Soy Agar (TSA) plates and incubated at 37C. Colonies were imprinted
onto plates supplemented with 10 mg/ml chloramphenicol. Chloramphenicol-
sensitive colonies were tested by PCR for the deletion of sprF1/sprG1 and
then confirmed by northern blot (Figure S7).
RNA Extractions, Northern Blots, and Half-Life Determinations
RNA extractions were performed as previously described (Chabelskaya et al.,
2010). The DNA probes for RNA detection are listed in Table S4. Total RNAs
(10 mg) were separated on denaturing PAGE and transferred onto Zeta-Probe
GT membranes (Bio-Rad). Specific 30-end digoxigenin-labeled probes were
hybridized with DIG Easy Hyb solution overnight at 37C, washed, revealed
by an antidigoxigenin antibody-AP (Roche), exposed, and then viewed with
the ImageQuant LAS4000 imager (GE Healthcare). Quantifications were
performed with the ImageQuant and normalized to 5S rRNA or tmRNA. For
the RNA half-life measurements, S. aureus was cultured overnight, diluted
1:100, then grown for an additional 5 hr at 37C to the E phase, and then incu-
bated with 200 mg 3 ml1 of rifampicin for 1–120 min.
RACE End Mapping
Primers used are shown in Table S4. Total RNAs (5 mg) from S. aureus N315
were circularized using T4RNA Ligase (Promega). After precipitation, the reac-
tion was reverse transcribed by the M-MLV RT (Promega) using primer R1.
Two PCR reactions were performed with Taq polymerase (Invitrogen) using
R2-F1 and R2-F2 primers, respectively. The PCR products were cloned in
pGEM vector (Promega), transformed into E. coli DH5a, and sequenced with
M13 reverse vector primer using MegaBACE DNA sequencers (Amersham
Pharmacia Biotech).
In Vitro Transcription, RNA Labeling, and Translation Assays
All the RNAs used in this study were transcribed from PCR-amplified tem-
plates using N315 genomic DNA and forward primers containing a T7 pro-
moter sequence (Table S4). PCR-generated DNA was used as a template
for transcription using a MEGAscript T7 kit (Ambion). RNA was gel-purified,
eluted, and ethanol precipitated. 50 end labeling of RNA was performed
as previously described (Antal et al., 2005). In vitro translation of [35S]-methi-
onine was performed (Sayed et al., 2012b) using an E. coli S30 Extract
System for Linear Templates (Promega), following the manufacturer’s
instructions.
Gel-Shift Assays and Toeprints
Gel retardation assays were performed as previously described (Antal et al.,
2005). For the labeled gel shift, 0.4 pmol of labeled SprF1 was incubated
with various concentrations (0.1–8 pmol) of unlabeled SprG1. For the unla-
beled gel shift, 1 pmol of SprG1WT, SprG1-50ORF, or SprG1-30 was incubated
with 0.5 or 1 pmol of SprF1. RNA mixes were incubated in binding buffer
(80 mM K-HEPES [pH 7.5], 4 mM MgCl2, 330 mM KCl) for 20 min at 30
C
before native gel separation. Toeprint assays were performed (Chabelskaya
et al., 2010) using 0.25 pmol of SprG1 and 1 pmol of labeled ‘‘SprG1-Toe’’
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Protein Extractions, Cell Fractionations, and Western Blots
Protein extracts and cell fractionations were performed as previously
described (Sayed et al., 2012a, 2012b). Bradford assays were performed on
the samples and equal amounts of intracellular, extracellular, cytosolic, and
membrane proteins were used for the western blots and antibacterial assays.
For the western blots, the samples were separated on 16% Tricine SDS-PAGE
and transferred onto Hybond-P PVDF membrane (Amersham). After blocking,
membranes were incubated with one of the following primary antibodies:
monoclonal mouse anti-FLAG horseradish peroxidase (HRP) (Sigma);
polyclonal rabbit anti-M. luteus ATPase (Downer et al., 2002); rabbit anti-
S. aureus SarA (performed in the laboratory); mouse monoclonal anti-
S. aureus Protein A (Sigma); or sheep polyclonal anti-S. aureus Eap (Haggar
et al., 2005). After incubation with HRP-conjugated secondary antibodies,
the membranes were revealed using the ECL Plus Western Blotting Detection
kit (Amersham) and scanned with the LAS4000 imager. For the antibacterial
assays, the membrane extracts were dissolved in lysis buffer with 0.05%
Triton X-100, EDTA-free cocktail protease inhibitor, and 25% isopropanol,
and concentrated between 3 to 10 kDa with Centricon and Amicon Centrifugal
Filters (Millipore), following the manufacturer’s instructions.
SprG1 Induction, Growth, and Cell Death Experiments
Strains containing the relevant plasmids were grown in BHI for 2 hr 15 min at
37C to mid-E phase (OD600nm:1.5) and then incubated with 1 mM of aTc
inducer. For the kinetics, OD600nm was measured at each time point. To deter-
mine the effects of SprG1 WT and mutant inductions, cultures were prepared
by 2-fold serial dilutions of E phase cultures on BHI plates containing 1 mMaTc
and then incubated for 24 hr at 37C. For the cell death experiments, cultures
were incubated for 1 hr, washed with PBS, and then stained with a LIVE/DEAD
kit (Invitrogen) following the manufacturer’s instructions. Pictures of fluores-
cence-labeled cells were captured with a DM RXA2 microscope (Leica)
and a CoolSNAP HQ charge-coupled device camera (Photometrics) using
MetaVue software (Molecular Devices).
Hemolytic and Antibacterial Assays
The two peptides were synthesized (UMR 6226) at >99% purity as verified by
HPLC and MALDI-TOF and dissolved into 50% isopropanol. For the hemolytic
assays, human red blood cells (Etablissement Franc¸ais du Sang) were washed
three times and diluted to 5% in PBS. Peptide dilutions (75 ml) resulting from
serial halving in PBS were added into a V-bottomed 96-well plate with 75 ml
of 5% red blood cells. After 2 hr incubation at 37C, the plate was centrifuged
15min at 1,400 rpm, and the supernatant was transferred onto a newplate. The
absorbance of the released hemoglobin was measured at 414 nm. Positive
and negative controls were performed with 1% Triton X-100 and the same
amount of the vehicle (2.5% isopropanol), respectively. The results were ex-
pressed as a percentage of lysis as compared to the positive control (100%).
Antimicrobial activity was measured as previously described (Jorgensen and
Ferraro, 2009) against S. aureus (N315) and against two other Gram-negative
bacteria often associated with S. aureus infections, Escherichia coli (K12),
and Pseudomonas aeruginosa. The strains were grown inMueller-Hinton broth
until 108 CFU/ml (OD600nm:0.5). They were then diluted to obtain between 10
4
and 105 CFU per well of a flat-bottomed 96-well plate and incubated with pep-
tide dilutions resulting from serial halving in PBS buffer. Cultures were grown
for 20 hr with vigorous shaking at 37C, and the bacterial growthwas evaluated
by measuring the absorbance of the bacterial culture at 600 nm using a micro-
plate reader (BioTek). Negative controls were performed with 0.3% isopro-
panol. Positive controls were performed with either pure nisin or cecropin for
Gram-positive and -negative bacteria, respectively. To evaluate the biological
activity of membrane extracts purified from strains DsprG1/sprF1, isogenic
pALC-USprG1, and pALC-USprG1-STOP1,14, S. aureus strain N315 was culti-
vated in the absence (5% isopropanol as a control) or presence of 230 mg/ml
membrane extracts. Nisin (100 mg/ml) was used as a positive control.
Statistical Analysis
Data are expressed as mean ± SD of at least three to four independent exper-
iments. Significant differences were evaluated using the t test. Standard devi-
ations: *p < 0.05; **p < 0.01; and ***p < 0.001were considered to be statistically
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